// App-Quantinova.ai

398 : Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

Researchers

Presenter

  • Yuya Sasaki

Principal Investigators

  • Hagop M. Kantarjian

  • Nicholas J. Short

  • Nitin Jain

  • Koji Sasaki

  • Farhad Ravandi

  • Marina Konopleva

  • Guillermo Garcia-Manero

  • Latasha Little

  • Curtis Gumbs

  • Li Zhao

  • P Andrew Futreal

  • Feng Wang

  • Ken Furudate

  • Rebecca Garris

  • Koichi Takahashi

  • Elias Jabbour

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Associate Professor of Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Genetics, UT MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • 1.MD Anderson Cancer Center, Houston, TX

  • Department of Genetics, UT MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Ponatinib

  • dasatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00390793

  • NCT01424982

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved